GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » 5-Year Dividend Growth Rate

NurExone Biologic (TSXV:NRX) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic 5-Year Dividend Growth Rate?

NurExone Biologic's Dividends per Share for the three months ended in Sep. 2024 was C$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

NurExone Biologic's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, NurExone Biologic's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of NurExone Biologic's 5-Year Dividend Growth Rate

For the Biotechnology subindustry, NurExone Biologic's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's 5-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's 5-Year Dividend Growth Rate falls into.



NurExone Biologic 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


NurExone Biologic  (TSXV:NRX) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

NurExone Biologic's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Sep. 2024 )/ EPS without NRI (Q: Sep. 2024 )
=0/ -0.027
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NurExone Biologic 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines